Navigation Links
Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
Date:12/11/2013

SAN FRANCISCO, Dec. 11, 2013 /PRNewswire/ -- Sutro Biopharma today announced that the company has secured $26 million in a Series D financing. The additional financing will fund the expansion of Sutro's proprietary immuno-oncology product pipeline.  Sutro is developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, utilizing the company's cell-free protein synthesis technology.

The financing closed in December 2013 and was led by Sutro's existing investors: Alta Partners, Amgen Ventures, Celgene Corporation, Lilly Ventures, Skyline Ventures and SV Life Sciences. Sutro has raised over $90 million since its founding in 2003.

"Our ability to accelerate the development of our immuno-oncology portfolio is now in hand. This successful financing further demonstrates the enthusiasm of our investors in Sutro and is a tremendous validation of our emerging product pipeline together with our broad technology platform. Sutro is an emerging leader in the rapid development of novel and differentiated products targeting immuno-oncology pathways," said William Newell, chief executive officer of Sutro Biopharma. "We will continue to advance candidates that leverage the immune system's natural ability to fight cancer, with the goal of establishing next generation immuno-oncology products that will transform cancer therapy for physicians and patients."  

About Sutro Biopharma

Sutro Biopharma, located in South San Francisco, is developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies. These therapeutics will significantly extend the clinical impact of current oncology therapeutic approaches and are beyond what can be envisioned with current, cell-based expression technologies. Sutro's biochemical synthesis technology, which underpins these therapeutics, allows the rapid and systematic exploration of many protein drug variants to identify drug candidates. Once the product candidates are identified, production can be rapidly and predictably scaled up to commercial levels. Sutro has established a Good Manufacturing Practice (cGMP) facility for the production of clinical supplies of materials using its biochemical protein synthesis platform. Sutro has formed multiple partnerships with biopharma companies utilizing its technology, including a collaboration with Celgene Corporation to design and develop novel antibody drug conjugates and bispecific antibodies as well as to manufacture a proprietary Celgene antibody.

For more information, visit www.sutrobio.com.

Media Contact:
Martina Schwarzkopf, Ph.D.
Russo Partners
(212) 845-4292
(347) 591-8785 (mobile)
martina.schwarzkopf@russopartnersllc.com


'/>"/>
SOURCE Sutro Biopharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PDL BioPharma Provides Fourth Quarter 2013 Revenue Guidance of $109 Million
2. Array BioPharma Provides Clinical Update On ARRY-614 For Myelodysplastic Syndromes At The 2013 American Society Of Hematology Meeting
3. Array BioPharma Provides Clinical Update On Filanesib (ARRY-520) For Multiple Myeloma At The 2013 American Society of Hematology Meeting
4. Stocks Outperformed the Broader Markets: Facebook Inc, Twitter Inc, CF Industries Holdings, Green Mountain Coffee Roasters, Arca Biopharma
5. Corporate News, Acquisitions: Herbalife Ltd, 3D Systems Corporation, Federal National Mortgage Association, Galena Biopharma Inc, Oncomed Pharmaceuticals
6. Roundtable of Biopharma Industry Leaders Offers Insights to Market Access Challenges
7. Global Markets for Bioseparations for Biopharmaceutical Manufacturing to Jump to $6 Billion by 2018
8. Array BioPharma Announces Management Team Change
9. Rapid Delivery Program Product Portfolio Expands to Biopharmaceutical Injectable Market
10. MGB Biopharma Adds its Support to European Antibiotic Awareness Day
11. Array BioPharma To Present At The Jefferies 2013 Global Healthcare And Piper Jaffray 25th Annual Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease ... end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the end ... mandated by certain health insurance regulations. ... The best time to get a flu shot is by the end ...
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected Warren ... James C. Puffer upon his retirement. Dr. Newton will serve in the position of ... end of 2018. Upon assuming the role of President and CEO on January 1, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
Breaking Medicine News(10 mins):